Long term sequelae of sex steroid treatment in the management of constitutionally tall stature.
OBJECTIVE
To evaluate possible long term side effects of high doses of sex steroids in the management of constitutionally tall stature, with special attention to hypothalamic-gonadal function.


METHODS
Sixty four tall adult men and 180 tall adult women, who received supraphysiological doses of sex hormones during puberty, were interviewed in a standardised way at a mean follow up period of 10 years after cessation of treatment. Sixty one untreated tall adult men and 94 untreated tall adult women served as controls.


RESULTS
The majority of the subjects were satisfied with their decision regarding hormone treatment. Seventy seven per cent of the women and 78% of the men reported one or more side effects during treatment. Most side effects were mild. In women, only 3% stopped treatment because of an adverse event; in men, the reported side effects never stopped treatment. The frequency of reported side effects in women was higher during treatment with high doses of oestrogens than during oral contraceptive use, indicating a dose dependent relationship. Amenorrhoea of longer than six months after cessation of therapy was found in 5%. Menstrual cycle characteristics of previously treated women were comparable with controls. Malignancy was not reported. Information about a total of 127 pregnancies was obtained and revealed no distinct differences in details and outcome between previously treated women and men, and controls.


CONCLUSIONS
At a mean follow up of 10 years there is no evidence that pharmacological doses of sex hormones have a long term effect on reproductive function. However, this period is still too short to draw definite conclusions.
D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D012739:Gonadal Steroid Hormones / Q000009:adverse effects*; D006130:Growth Disorders / Q000188:drug therapy*; D006131:Growth Inhibitors / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000009:adverse effects; D008598:Menstruation / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D012098:Reproduction / Q000187:drug effects*; D013739:Testosterone / Q000009:adverse effects
D003276:Contraceptives, Oral; D004338:Drug Combinations; D012739:Gonadal Steroid Hormones; D006131:Growth Inhibitors; D013739:Testosterone; D004997:Ethinyl Estradiol; D008525:Medroxyprogesterone